Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing

References

• Akinyemiju, T., et al., 2017. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015. Jama oncol, 3, 1683–1691.
   PubMed Web of Science ®Google Scholar
• Asham, E.H., Kaseb, A., and Ghobrial, R.M.J.S.C., 2013. Management of hepatocellular carcinoma. The surgical clinics of North America, 93 (6), 1423–1450.
   PubMed Web of Science ®Google Scholar
• Calistri, D., et al., 2005. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. Journal of Cellular Physiology, 204, 484–488.
   PubMed Web of Science ®Google Scholar
• Ding, X. X., et al., 2017. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget, 8, 55715–55730.
   PubMedGoogle Scholar
• Eeles, R. A., et al. 2013. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 45, 385–391.
   PubMed Web of Science ®Google Scholar
• Forner, A., Reig, M., and Bruix, J., 2018. Hepatocellular carcinoma. The lancet, 391 (10127), 1301–1314.
   PubMed Web of Science ®Google Scholar
• Fu, Y.T., et al., 2017. Valproic acid, targets papillary thyroid cancer through inhibition of C-met signalling pathway. Am j transl res, 9, 3138–3147.
   PubMed Web of Science ®Google Scholar
• Grundy, M., and Narendran, A., 2022. The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents. Frontiers in pediatrics, 10, 910268.
   Web of Science ®Google Scholar
• Hsu, H. C., et al., 1994. Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients. Cancer, 73, 42–47.
   PubMed Web of Science ®Google Scholar
• Hu, Y., et al., 2021. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder. Signal Transduction and Targeted Therapy, 6, 55.
   PubMed Web of Science ®Google Scholar
• Ikeda, S., et al., 2018. Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. Oncologist, 23, 586–593.
   PubMed Web of Science ®Google Scholar
• Lee, A., et al., 2018. Use of the Ion AmpliSeq Cancer Hotspot Panel in clinical molecular pathology laboratories for analysis of solid tumours: With emphasis on validation with relevant single molecular pathology tests and the Oncomine Focus Assay. Pathology, Research and Practice, 214, 713–719.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2017. Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China. Medicine (Baltimore ), 96, e6508.
   PubMed Web of Science ®Google Scholar
• Rashed, W.M., et al., 2020. Hepatocellular Carcinoma (Hcc) in Egypt: A comprehensive overview. Journal of the egyptian national cancer institute, 32 (1), 5.
   PubMed Web of Science ®Google Scholar
• Sung, H., et al., 2021. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer journal for clinician, 71, 209–249.
   PubMed Web of Science ®Google Scholar
• Wu, E. M., et al., 2018. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Research, 4, 66.
   PubMedGoogle Scholar
• Yan, Y.Y., et al., 2021. Cell-free DNA: Hope and potential application in cancer. Frontiers in cell and developmental biology, 9, 639233.
   PubMedGoogle Scholar
• Yang, D., et al., 2013. Association analysis between Mdr1 gene polymorphisms and risk of hepatocellular carcinoma in Chinese population. Biomarkers, 18 (3), 236–241.
   PubMed Web of Science ®Google Scholar
• Yang, J.D., et al., 2011. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clinical gastroenterology and hepatology, 9 (1), 64–70.
   PubMed Web of Science ®Google Scholar
• Ziada, D. H., et al., 2016. Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: A single center study. Journal of the Egyptian National Cancer Institute, 28, 257–262.
   PubMed Web of Science ®Google Scholar
• Zhang, W. S., et al., 2020. Increased level of systolic blood pressure in hepatocellular carcinoma patients with diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity, 13, 1979–1988.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2018. Function of the C-met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Molecular cancer, 17 (1), 45.
   PubMedGoogle Scholar
• Zhao, C., and Nguyen, M.H., 2016. Hepatocellular carcinoma screening and surveillance: Practice guidelines and real-life practice. Journal of clinical gastroenterology, 50 (2), 120–133.
   PubMed Web of Science ®Google Scholar